Cargando…

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy

Anti-tumor necrosis factor alpha (ATA) therapy plays a significant role in the treatment of moderate to severe inflammatory bowel disease (IBD). There are concerns regarding risks associated with their use, including malignancy and, specifically, lymphoma. Many previous studies have sought to determ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahmus, Jessica, Rosario, Michelle, Clarke, Kofi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501969/ https://www.ncbi.nlm.nih.gov/pubmed/32982364 http://dx.doi.org/10.2147/CEG.S237646

Ejemplares similares

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
por: Altwegg, Romain, et al.
Publicado: (2014)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy
por: Guillén, M. Carmen, et al.
Publicado: (2020)

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease
por: Colombo, Giorgia, et al.
Publicado: (2023)

Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C
por: Williams, Isabelle, et al.
Publicado: (2022)

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Holmgren, Johanna, et al.
Publicado: (2022)

Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19
por: Li, Xiao-Zhi, et al.
Publicado: (2021)

Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
por: Cha, Jae Myung, et al.
Publicado: (2017)

Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease
por: Paschou, Stavroula A., et al.
Publicado: (2018)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON(®) Gold Testing Useful?
por: Lovatt, Jessica, et al.
Publicado: (2021)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
por: Li, Dalin, et al.
Publicado: (2022)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Anti-integrin therapy for inflammatory bowel disease
por: Park, Sung Chul, et al.
Publicado: (2018)

Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease
por: Stallhofer, Johannes, et al.
Publicado: (2023)

Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease
por: Karmi, Naomi, et al.
Publicado: (2021)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases
por: Rezaie, Ali
Publicado: (2014)

Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature
por: Parekh, Ravish, et al.
Publicado: (2014)

Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy
por: Wang, Xinyu, et al.
Publicado: (2020)

Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
por: Mohagheghi Darehranj, Samaneh, et al.
Publicado: (2020)

A Multi-mRNA Prognostic Signature for Anti-TNFα Therapy Response in Patients with Inflammatory Bowel Disease
por: Sakaram, Suraj, et al.
Publicado: (2021)

Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
por: Mazhar, Faizan, et al.
Publicado: (2020)

Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease
por: Shu, Weigang, et al.
Publicado: (2019)

Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis
por: Siebenhüner, Alexander R., et al.
Publicado: (2021)

Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
por: Park, Yong Eun, et al.
Publicado: (2022)

Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease
por: Mishra, Neha, et al.
Publicado: (2022)

Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis
por: Xie, Wenhui, et al.
Publicado: (2022)

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
por: Aardoom, Martine A., et al.
Publicado: (2019)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

Addressing Fecal Incontinence in Inflammatory Bowel Disease Patients: A Messy Problem
por: Clarke, Kofi
Publicado: (2021)

Anti-TNF Therapy in Crohn’s Disease
por: Adegbola, Samuel O., et al.
Publicado: (2018)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hc3uri7qaffmlmjlf0tbdhmcbv